Quantum Biosciences Selected for Swissnex AIT 2025

We are pleased to announce that Quantum Biosciences has been selected for the 2025 Academia-Industry Training (AIT) program, a high-stakes "sciencepreneur" accelerator organized by Swissnex in India and Venturelab.

Our inclusion in the AIT program serves as a catalyst for our mission to bring quantum-enabled diagnostics to the global stage. By acting as a strategic bridge between the deep-tech ecosystems of India and Switzerland, the program provides a unique platform to transition our "Diagnostic Blind Window" solution from R&D toward global clinical validation.

The journey began this November with an intensive India Camp in Bengaluru. This week served as a high-impact immersion into the local and international deep-tech landscape. Rather than traditional classroom training, the camp provided practical opportunities to refine our narrative and engage with the broader ecosystem.

Key highlights of the India Camp included:

• Pitching at Scale: We had the opportunity to refine and deliver our pitch at the Bengaluru Tech Summit (BTS) and during a curated Networking Mixer at the Swissnex office, engaging with investors and industry veterans.
• Design Thinking & Local Markets: Educational sessions focused on "Designing for India," emphasizing the importance of design thinking in creating products specifically tailored to the unique needs of the Indian healthcare market.
• Regulatory Frameworks: A deep dive into the regulatory landscape for med-tech companies in India, providing a clear roadmap for navigating local compliance and market entry.
• Industry Immersions: First-hand site visits to industry leaders, including the BioCon center, 4basecare, and the life sciences division of ITC, offering invaluable insights into scaling biotech and deep-tech ventures.
• Cross-Border Exchange: High-level discussions with fellow med-tech founders from both Bengaluru and Switzerland, fostering a collaborative spirit that bridges these two world-class innovation hubs.

As a participant in the AIT program, Quantum Biosciences has gained a strategic gateway into the Swiss innovation landscape—arguably the world’s most sophisticated hub for MedTech and Life Sciences.

Looking ahead to the Swiss Camp in March 2026, our strategic objectives are centered on leveraging this network to facilitate high-level engagement within the Swiss ecosystem:

• R&D Synergy: Exploring potential research collaborations with world-class hubs like ETH Zurich to further refine our quantum sensing capabilities.
• Clinical Validation: Engaging with the global diagnostic and pharma community in Basel—home to leaders like Roche and Novartis—to align our predictive platform with international standards for toxicity monitoring.
• Regulatory & Market Entry: Working with Swiss experts to navigate the CE-IVDR and Swissmedic pathways for European market access.

Selection into the Swissnex AIT program is more than an honor; it is a catalyst. By combining the rapid innovation of Bengaluru with the precision and regulatory excellence of Switzerland, we are accelerating our ability to help clinicians move from reactive damage control to proactive, personalized care.